mast-cells-microenvironment-hepatocellular-carcinoma-confer-favorable

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

The insights provided by in-situ detection of immune cells within hepatocellular carcinoma (HCC) might present information on patient outcomes. Studies ...

Charles University

In this retrospective study on 67 patients with hepatocellular carcinoma (HCC), after tumor resection, we evaluated the significance of CD3+ and CD8+ T-lymphocytes and CD20+ B-lymphocytes in tumor and non-tumor liver for time to recurrence (TTR), disease-free survival (DFS) and overall survival. After immunohistochemical staining, the density of nucleated lymphocyte profiles (Q) was estimated stereologically in the tumor center (TC), inner margin (inn M), outer margin (out M), peritumor and non-tumor liver. In TC, intermediate and high Q of CD8+ cells predicted longer TTR, whereas CD3+ and CD20+ were predictive only at high Q. DFS was predicted by high Q of CD3+, CD8+ and CD20+ cells in TC. The inn M harbored smaller Q of CD3+, CD8+ and CD20+ lymphocytes than out M. In contrast to out M, high T-cells' Q and intermediate and high B-cell Q in inn M predicted longer TTR and DFS. High inn M/out M Q ratios of CD3+ and CD20+ cells were associated with longer TTR and DFS, whereas high inn M/out M Q ratio of CD8+ was predictive only for DFS. Patients with intermediate-high Q of combined CD8+ and CD20+ cells in inn M showed longer TTR and DFS, compared to CD8+-high or CD20+-high alone. Our findings highlight overall heterogeneity of the tumor invasive margin, the importance of inn M, and the predictive role of B-cells.

T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis.

Hepatocellular carcinoma (HCC) is a global healthcare challenge, which affects more than 815,000 new cases every year. Activated hepatic stellate cells (aHSCs) remain the principal cells that drive HCC onset and growth. aHSCs suppress the anti-tumor immune response through interaction with different immune cells. They also increase the deposition of the extracellular matrix proteins, challenging the reversion of fibrosis and increasing HCC growth and metastasis. Therapy for HCC was reported to activate HSCs, which could explain the low efficacy of current treatments. Conversely, recent studies aimed at the deactivation of HSCs show that they have been able to inhibit HCC growth. In this review article, we discuss the role of aHSCs in HCC pathophysiology and therapy. Finally, we provide suggestions for the experimental implementation of HSCs in HCC therapies.

Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies.

The prognostic significance of mast cells and different phenotypes of macrophages in the microenvironment of hepatocellular carcinoma (HCC) following resection is unclear. We aimed in this study to assess the local distribution of infiltrating macrophages and mast cells of specific phenotypes in tissues of HCC and to evaluate their prognostic values for survival of post-surgical patients.

Esraa Ali

Laboratory of Translational Cancer Genomics,
Biomedical Center,
Faculty of Medicine in Pilsen,
Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen

Charles University

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Esraa Ali

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Laboratory of Translational Cancer Genomics,Biomedical Center,Faculty of Medicine in Pilsen,Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen

Charles University

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Laboratory of Translational Cancer Genomics,
Biomedical Center,
Faculty of Medicine in Pilsen,
Laboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen